PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs that regulate gene expression by targeting post-translational control (PTC) mechanisms in orphan diseases.
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Technology applications include deep-brain stimulation, laser catheters, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene and stem cell therapies to the brain. The ClearPoint® Neuro Navigation System is FDA cleared, CE-marked, and installed in 60 active clinical sites in the United States. The Company’s SmartFlow® Cannula is being used in partnership with 20+ individual biologics and drug delivery companies from preclinical research to late stage regulatory trials in the U.S., EU and Asia. To date, more than 3,600 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners.
Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We also provide non-GLP toxicology and biodistribution services in primates and rodents to support the development of gene-based therapies. We deliver cutting edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.